SCHEDULE: Wellington Management Discloses 4.28% Stake in Akero

Wellington Management Group and its affiliates reported a 4.28% beneficial ownership stake in Akero Therapeutics, Inc. as of June 30, 2025, in its latest Schedule 13G amendment.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively reported beneficial ownership of 3,409,946 shares of Akero Therapeutics, Inc. Common Stock.
• This aggregate amount represents 4.28% of Akero Therapeutics, Inc.'s class of securities.
• The reporting entities hold shared voting power over 2,924,691 shares and shared dispositive power over 3,409,946 shares.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a change from previous disclosures.

Sentiment

Score: 5

Explanation: The filing is a factual regulatory disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Akero Therapeutics, Inc.'s future outlook.

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership by an institutional investor and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding the holdings of a significant institutional investor, Wellington Management Group LLP and its affiliates.

Key Dates

Keywords

Akero Therapeutics, Wellington Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, AKRO